Bridgefront Capital LLC Raises Stock Position in Takeda Pharmaceutical Co. $TAK

Bridgefront Capital LLC raised its stake in shares of Takeda Pharmaceutical Co. (NYSE:TAK) by 72.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 83,733 shares of the company’s stock after purchasing an additional 35,250 shares during the period. Bridgefront Capital LLC’s holdings in Takeda Pharmaceutical were worth $1,226,000 at the end of the most recent quarter.

Several other institutional investors have also modified their holdings of the stock. Royal Bank of Canada increased its stake in shares of Takeda Pharmaceutical by 11.0% during the first quarter. Royal Bank of Canada now owns 441,054 shares of the company’s stock worth $6,558,000 after purchasing an additional 43,706 shares in the last quarter. AQR Capital Management LLC lifted its stake in Takeda Pharmaceutical by 43.6% in the 1st quarter. AQR Capital Management LLC now owns 195,740 shares of the company’s stock valued at $2,911,000 after buying an additional 59,442 shares in the last quarter. Goldman Sachs Group Inc. boosted its holdings in Takeda Pharmaceutical by 15.0% in the 1st quarter. Goldman Sachs Group Inc. now owns 5,320,793 shares of the company’s stock worth $79,120,000 after buying an additional 692,404 shares during the last quarter. Focus Partners Wealth boosted its holdings in Takeda Pharmaceutical by 4.1% in the 1st quarter. Focus Partners Wealth now owns 82,738 shares of the company’s stock worth $1,230,000 after buying an additional 3,239 shares during the last quarter. Finally, Sivia Capital Partners LLC purchased a new stake in Takeda Pharmaceutical during the 2nd quarter worth approximately $351,000. Institutional investors and hedge funds own 9.17% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts have commented on TAK shares. Wall Street Zen raised Takeda Pharmaceutical from a “hold” rating to a “strong-buy” rating in a report on Saturday, January 31st. Morgan Stanley initiated coverage on Takeda Pharmaceutical in a research note on Tuesday, January 13th. They issued an “overweight” rating on the stock. Zacks Research raised Takeda Pharmaceutical from a “strong sell” rating to a “hold” rating in a research note on Tuesday, March 3rd. Finally, Weiss Ratings restated a “hold (c-)” rating on shares of Takeda Pharmaceutical in a report on Monday, December 29th. One investment analyst has rated the stock with a Buy rating and two have given a Hold rating to the company. Based on data from MarketBeat, the company has an average rating of “Hold”.

Takeda Pharmaceutical Stock Down 0.1%

TAK stock opened at $17.76 on Friday. The company has a market cap of $56.50 billion, a price-to-earnings ratio of 73.98 and a beta of 0.01. The company has a current ratio of 1.19, a quick ratio of 0.65 and a debt-to-equity ratio of 0.56. Takeda Pharmaceutical Co. has a 12 month low of $12.99 and a 12 month high of $18.82. The firm has a 50-day moving average of $17.44 and a two-hundred day moving average of $15.56.

Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, January 29th. The company reported $0.95 earnings per share for the quarter, topping the consensus estimate of $0.55 by $0.40. The business had revenue of $6.75 billion for the quarter, compared to analysts’ expectations of $7.81 billion. Takeda Pharmaceutical had a return on equity of 10.60% and a net margin of 2.58%. As a group, analysts forecast that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited (NYSE: TAK) is a Tokyo-based, multinational biopharmaceutical company with roots dating back to 1781. The company researches, develops, manufactures and commercializes pharmaceutical and biopharmaceutical products for patients worldwide. Takeda is publicly listed and operates as a fully integrated R&D-driven healthcare company focused on delivering specialty medicines and therapies across a range of therapeutic areas.

Takeda’s main business activities encompass discovery and development of prescription medicines, clinical development and regulatory affairs, manufacturing of small molecules and biologics, and global commercial operations.